Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $775.03M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.26M
Average 1.02M
GLUE EBITDA Margin
EBITDA as a percentage of revenue.
Monte Rosa Therapeutics, Inc.NASDAQ: GLUE
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -1007.6%
EBITDA Margin was -1007.6% in Q1 FY2026, down 1066.2 pp from a year earlier. On a trailing-twelve-month basis it was -287.6%, down 298.7 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -49.2% for the fiscal year ending Dec 2026, down from -25.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1007.6%+574.1 pp QoQ
- Last fiscal yearDec 2025
- -25.4%+56.6 pp YoY
- LTMMar 2026
- -287.6%-298.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1066.2 pp | -266.5 pp | +799.7 pp |
| 1 year | +56.6 pp | -23.9 pp | -80.5 pp |
| 3 years | — | -102.7 pp | — |
| 5 years | -74.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -25.4%
- Year-over-year change
- +56.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -25.4% | +56.6pp |
| FY2024 | 2024-12-31 | -82.0% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How GLUE compares with its peers on the latest reported figures
- GLUE's LTM Mar 2026 EBITDA Margin of -287.6% is the 3rd highest of the 4 companies compared; the peer median is -242.2%.
- Its year-over-year change of -298.7 pp is the lowest of 4, against a peer median of -44.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
| LTM Mar 2026 | -242.2% | -232.7 pp | +164.2 pp | |
| LTM Mar 2026 | -287.6% | -298.7 pp | — | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| Peer median (excluding GLUE) | -242.2% | -44.6 pp | +147.4 pp | |
Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 75.62M | 123.67M |
| Cost of Revenue | 0 | 0 | 6.22M | 8.12M | 8.36M |
| Gross Profit | 0 | 0 | (6.22M) | 67.5M | 115.32M |
| Gross Margin | — | — | — | 89.3% | 93.2% |
| Research & Development | 57.16M | 85.06M | 105.05M | 121.56M | 141.5M |
| Selling, General & Admin | 15.73M | 27.32M | 32.04M | 35.17M | 36.38M |
| Operating Expenses | 72.88M | 112.38M | 137.09M | 148.61M | 169.52M |
| Depreciation & Amortization | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| EBITDA | (71.83M) | (100.99M) | (128.79M) | (62.01M) | (31.37M) |
| EBITDA Margin | — | — | — | -82.0% | -25.4% |
| Operating Income | (72.88M) | (112.38M) | (143.31M) | (81.11M) | (54.21M) |
| Operating Margin | — | — | — | -107.3% | -43.8% |
| Interest Income | 46K | 3.76M | 9.33M | 10.57M | 12.94M |
| Interest Expense | 0 | 3.76M | 0 | 0 | 0 |
| Other Income / Expenses | (1.08M) | 3.88M | 8.3M | 10.98M | 14.49M |
| Income Before Tax | (73.96M) | (108.5M) | (135.01M) | (70.13M) | (39.72M) |
| Pre-Tax Margin | — | — | — | -92.7% | -32.1% |
| Income Tax Expense | 0 | 0 | 338K | 2.57M | (1.1M) |
| Net Income | (73.96M) | (108.5M) | (135.35M) | (72.7M) | (38.63M) |
| Net Margin | — | — | — | -96.1% | -31.2% |
| EPS (Basic) | (1.59) | (2.30) | (2.63) | (0.98) | (0.46) |
| EPS (Diluted) | (1.59) | (2.30) | (2.63) | (0.98) | (0.46) |
| Weighted Avg Shares | 46.54M | 47.23M | 51.4M | 73.91M | 83.07M |
| Weighted Avg Shares (Diluted) | 46.54M | 47.23M | 51.4M | 73.91M | 83.07M |
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
Intrinsic Alpha fair value
Locked
Current Price
$9.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.